Show
Sort by
-
Personalized medicine for allergy treatment : allergen immunotherapy still a unique and unmatched model
-
Cabbage and fermented vegetables : from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19
-
- Journal Article
- A1
- open access
ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy
-
A 300 IR sublingual tablet is an effective, safe treatment for house dust mite induced allergic rhinitis : an international, double-blind, placebo-controlled, randomized phase III clinical trial
-
Reduction in rescue medication use in patients treated with the 300IR house dust mite SLIT tablet
-
Relief of ocular symptoms in patients with house dust mite allergic rhinitis treated with the 300IR house dust mite SLIT tablet
-
- Journal Article
- A1
- open access
Nrf2-interacting nutrients and COVID-19 : time for research to develop adaptation strategies
-
Efficacy of a 300IR house dust mite tablet is consistent when evaluated by the proportion of symptom-controlled days: Results of a large randomised, double-blind placebo-controlled, multicentre trial
-
Efficacy and safety of the 300 IR sublingual tablet for the treatment of house dust mite-associated allergic rhinitis : a multicentre, international, dbpc, randomized phase III clinical trial
-
Quality of life in patients with house dust mite-associated allergic rhinitis treated with 300IR house dust mite sublingual tablet : results of a large multicentre clinical trial